RxDoctor Payments Data

Stuart Kipper, MD

Internal Medicine · Vista, CANPI 1114956570

Payments from drug & device makers

$941in general payments, 2019–2025

Across 58 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$363
  • Sumitomo Pharma America, Inc.$120
  • Lilly USA, LLC$79
  • Johnson & Johnson$75
  • Novo Nordisk$73
  • Antares Pharma, Inc.$71
  • plus $161 from 7 others

What the payments were for

  • Food & beverage$91197%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$941 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$208,040
Medicare patients
172
Services billed
29,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$45,573
BiktarvyBictegrav/Emtricit/Tenofov Ala12$45,288
EliquisApixaban54$43,275
MounjaroTirzepatide32$36,199
LinzessLinaclotide24$25,735
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$25,139
GemtesaVibegron33$21,333
WegovySemaglutide16$21,223
NamzaricMemantine Hcl/Donepezil Hcl27$18,729
MovantikNaloxegol Oxalate16$15,086
Testosterone60$11,677
Memantine Hcl ErMemantine Hcl24$4,511
VascepaIcosapent Ethyl11$3,928
Clonidine17$2,702
Midodrine Hcl28$2,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$73$66,79650 claims
AbbVieLinzess, Namzaric$363$44,46451 claims
PfizerEliquis$14$43,27554 claims
Lilly USA, LLCMounjaro$79$36,19932 claims
Sumitomo Pharma America, Inc.Gemtesa$120$21,33333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →